In a new international collaborative study published in the journal Nature, researchers have learned why so many targeted drugs for medulloblastoma fail in clinical trials. “This new research provides an explanation for why most clinical trials fail, and proposes a new approach to improve the success of medulloblastoma therapy,” said Robert Wechsler-Reya, Ph.D, director of the Tumor Initiation and Maintenance Program at SBP and one of the study authors.
In a new international collaborative study published in the journal Nature, researchers have learned why so many targeted drugs for medulloblastoma fail in clinical trials. “This new research provides an explanation for why most clinical trials fail, and proposes a new approach to improve the success of medulloblastoma therapy,” said Robert Wechsler-Reya, Ph.D, director of the Tumor Initiation and Maintenance Program at SBP and one of the study authors.